While fewer studies have focused on CDK inhibitors for T-ALL pre-clinical treatments compared to BET inhibitors, The CDK inhibitor dinaciclib suppresses c-MYC and cyclin T1, induces G2/M phase cell cycle arrest, and triggers apoptosis in T-ALL cells [67]. Here, MYC is linked to acute lymphoblastic leukemia.